Tour Atlantique 25e
1 Place de la Pyramide
92911 Paris La Défense Cedex
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. With the development of the CyberKnife® Robotic Radiosurgery System, Accuray revolutionized the field of radiosurgery, which was once confined to neurosurgical indications. The CyberKnife System can be used to treat tumors anywhere in the bodyincluding spine, lung, prostate, liver and pancreas.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. With the development of the CyberKnife® Robotic Radiosurgery System, Accuray revolutionized the field of radiosurgery, which was once confined to neurosurgical indications. The CyberKnife System can be used to treat tumors anywhere in the bodyincluding spine, lung, prostate, liver and pancreas. Today, theseextracranial treatments represent more than 50 percent of CyberKnife procedures and are some of the fastest growing applications, offering new options and new hope for many patients.
The CyberKnife System is the first and only commercially available radiosurgery system to combine image guidance and robotic mobility. These two elements enable the CyberKnife System to treat tumors from literally hundreds of angles throughout the body, enabling treatment with pinpoint precision and minimizing damage to surrounding healthy tissue.
Since the launch of the CyberKnife System, Accuray has undertaken a development strategy to allow clinicians to non-invasively treat tumors anywhere in the body with the highest levels of accuracy, in order to improve patient care and comfortably treat patients without invasive head or body frames.
The company has changed the way cancer is treated with a series of continuous system options that can track and compensate for tumor motion and eliminate the need for implanted fiducial markers.
In addition to Accuray’s commitment to the development of its cutting-edge technology, the company continues to invest in the clinical research required for oncology indications. The evidence from more than 500 peer-reviewed publications provides the foundation of support that drives physician adoption and patient access to treatment using the CyberKnife System.
Accuray completed a successful initial public offering in February 2007 and has been ranked in the Deloitte Technology Fast 500 since 2008 as one of the fastest growing companies in North America. In 2008 the World Economic Forum named Accuray to its premier list of ‘Technology Pioneers’, acknowledging the company’sdevelopment of life-changing technology and its potential for long-term impact on business and society. In 2009, Accuray’s CEO Euan Thomson was named an ‘Entrepreneur of the Year’ by Ernst & Young in its Northern California Health and Life Sciences category.
Accuray continues to demonstrate its leadership in the field of radiosurgery with more than 78 U.S. and foreign patents issued and more than 129 pending U.S. and foreign patent applications. The company has offices in California, Paris, Hong Kong and Tokyo with more than 450 employees worldwide
To date, the CyberKnife System has been used to treat more than 100,000 patients around the world, with more than 216 systems installed in leading hospitals throughout the Americas, Europe and Asia. CyberKnife usage continues to grow with more than 25 percent of all CyberKnife treatments occurring during the company’s fiscal year 2009 and additional clinical evidence supporting new indications being published on a continual basis.
Today, Accuray is committed not only to continuing its tradition of advancing the field of robotic radiosurgery, but also to providing its customers with the highest level of support in their ongoing efforts to fight cancer.
The CyberKnife System was first developed in 1987 by a team at Stanford lead by John R. Adler, M.D., a professor of neurosurgery and radiation oncology at Stanford University Medical Center. Dr. Adler had the vision todevelop a non-invasive robotic radiosurgery system with superior accuracy for treatment of tumors anywhere in the body. The revolutionary concept reached far beyond the practice of radiosurgery at the time, which restricted radiosurgery to the treatment of intracranial tumors. In 1990, Accuray Incorporated was founded.
Accuray first received FDA clearance for the CyberKnife System in 1999 for the treatment of tumors in the head, neck and upper spine. Then in 2001, the company received FDA clearance to introduce enhancements to the CyberKnife System for the treatment of tumors anywhere in the body.